Previous 10 | Next 10 |
home / stock / bpmuf / bpmuf news
New compound added to Basilea’s clinical pipeline; upon successful completion of preclinical profiling, start of phase 2 study planned for H1 2025 Upfront payments of USD 2 million Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, October 19, 2023...
Eight presentations on antibiotic ceftobiprole providing further evidence for its activity against methicillin-resistant Staphylococcus aureus (MRSA) and other clinically relevant pathogens Allschwil, Switzerland, October 17, 2023 Basilea Pharmaceutica Ltd, Allschw...
Seeking approval for Staphylococcus aureus bacteremia (SAB), acute bacterial skin and skin structure infections (ABSSSI), and community-acquired bacterial pneumonia (CABP) Prescription Drug User Fee Act (PDUFA) goal date set for April 03, 2024 Ad hoc announcement pur...
Allschwil, Switzerland, September 28, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that data from the successful phase 3 study ERADI...
2023-08-15 15:07:03 ET Basilea Pharmaceutica AG (BPMUF) Q2 2023 Results Conference Call August 15, 2023 10:00 AM ET Company Participants David Veitch - Chief Executive Officer Adesh Kaul - Chief Financial Officer Marc Engelhardt - Chief Medical Officer Conf...
2023-08-15 06:25:56 ET Basilea Pharmaceutica AG press release ( OTC:BPMUF ): 1H GAAP EPS of CHF2.42. Revenue of CHF84.9M (+47.4% Y/Y). For further details see: Basilea Pharmaceutica AG GAAP EPS of CHF2.42, revenue of CHF84.9M
Increase in Cresemba ® and Zevtera ® related revenue to CHF 80.5 million (+57% year-on-year) Increase in operating profit to CHF 36.9 million and net profit to CHF 31.9 million Increase in cash and restricted cash to CHF 112.9 million Full...
Seeking approval for Staphylococcus aureus bacteremia (SAB) , acute bacterial skin and skin structure infections (ABSSSI) , and community-acquired bacterial pneumonia (CABP) NDA eligible for P riority R eview Ad hoc announcement pursua...
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, June 08, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial or fungal infections, reported today that ...
Basel/Allschwil, Switzerland, April 26, 2023 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial or fungal infections, reported that shareholders approved all proposals of the board of directors...
News, Short Squeeze, Breakout and More Instantly...
Basilea Pharm Ag Akt Shs Company Name:
BPMUF Stock Symbol:
OTCMKTS Market:
China Yuchai International Limited (CYD) is expected to report for Q1 2024 Avid Bioservices Inc. (CDMO) is expected to report $0.03 for Q4 2024 Derwent London Plc (DWVYF) is expected to report for Q1 2024 Fresnillo Plc (FNLPF) is expected to report for Q1 2024 Basilea Pharmaceutic...
GreenTree Hospitality Group Ltd. American depositary shares each representing one Class A (GHG) is expected to report for Q1 2024 Air T Inc. (AIRT) is expected to report for Q4 2024 Alimentation-Couche Tard Inc. - Class A (Multiple Voting) (ANCTF) is expected to report for Q4 2024 Man...
Allschwil, Switzerland, June 20, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an asset purchase agreement w...